(function(dust){dust.register("metadata_tpl",body_0);functionbody_0(chk,ctx){returnchk.h("eq",ctx,{"block":body_1},{"key":ctx.getPath(false,["data","resourceType"]),"value":ctx.getPath(false,["constants","ES_RESOURCE_TYPE"])},"h").h("eq",ctx,{"block":body_17},{"key":ctx.getPath(false,["data","resourceType"]),"value":ctx.getPath(false,["constants","DC_RESOURCE_TYPE"])},"h").w("");}body_0.__dustBody=!0;functionbody_1(chk,ctx){returnchk.w("<div class=\"row\">").x(ctx.getPath(false,["data","mergedProposalBeamlines"]),ctx,{"block":body_2},{}).w("</div><hr> <div class=\"row\"><div class=\"col-12\">").h("abstract",ctx,{"block":body_16},{"abstract":ctx.getPath(false,["data","abstract"])},"h").w("</div></div>");}body_1.__dustBody=!0;functionbody_2(chk,ctx){returnchk.x(ctx.getPath(false,["data","mergedProposalBeamlines","0"]),ctx,{"block":body_3},{});}body_2.__dustBody=!0;functionbody_3(chk,ctx){returnchk.w("<div class=\"col\"><div class=\"myBorder-left\"><label> Proposal </label>").x(ctx.getPath(false,["data","mergedProposalBeamlines","0","proposal"]),ctx,{"else":body_4,"block":body_5},{}).w("</div></div><div class=\"col\"><div class=\"myBorder-left\"><label> Publication year </label>").x(ctx.getPath(false,["data","mintingYear"]),ctx,{"else":body_6,"block":body_7},{}).w("</div></div><div class=\"col\"><div class=\"myBorder-left\"><label> Beamline </label> ").x(ctx.getPath(false,["data","mergedProposalBeamlines","0","beamline"]),ctx,{"else":body_8,"block":body_9},{}).w("</div></div><div class=\"col\"><div class=\"myBorder-left\"><label> Session date </label>").x(ctx.getPath(false,["data","sessionDate"]),ctx,{"else":body_12,"block":body_13},{}).w("</div></div> <div class=\"col-4\"><div class=\"myBorder-left\"><label>Category </label>").x(ctx.getPath(false,["data","proposalType"]),ctx,{"else":body_14,"block":body_15},{}).w("</div></div> ");}body_3.__dustBody=!0;functionbody_4(chk,ctx){returnchk.w("<div class=\"padding-left-15\"> Not available</div>");}body_4.__dustBody=!0;functionbody_5(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","mergedProposalBeamlines","0","proposal"]),ctx,"h").w("</div>");}body_5.__dustBody=!0;functionbody_6(chk,ctx){returnchk.w("<div class=\"padding-left-15\"> Not available</div>");}body_6.__dustBody=!0;functionbody_7(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","mintingYear"]),ctx,"h").w("</div>");}body_7.__dustBody=!0;functionbody_8(chk,ctx){returnchk.w("<div class=\"padding-left-15\">Not available</div>");}body_8.__dustBody=!0;functionbody_9(chk,ctx){returnchk.h("eq",ctx,{"else":body_10,"block":body_11},{"key":ctx.getPath(false,["data","mergedProposalBeamlines","0","beamlineUrl"]),"value":"noLink"},"h");}body_9.__dustBody=!0;functionbody_10(chk,ctx){returnchk.w("<div class=\"padding-left-15\"><a href=\"").f(ctx.getPath(false,["data","mergedProposalBeamlines","0","beamlineUrl"]),ctx,"h").w("\" target=\"_blank\"> ").f(ctx.getPath(false,["data","mergedProposalBeamlines","0","beamline"]),ctx,"h").w(" </a></div>");}body_10.__dustBody=!0;functionbody_11(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","mergedProposalBeamlines","0","beamline"]),ctx,"h").w("</div>");}body_11.__dustBody=!0;functionbody_12(chk,ctx){returnchk.w("<div class=\"padding-left-15\"> Not available</div>");}body_12.__dustBody=!0;functionbody_13(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","sessionDate"]),ctx,"h").w("</div>");}body_13.__dustBody=!0;functionbody_14(chk,ctx){returnchk.w("<div class=\"padding-left-15\"> Not available</div>");}body_14.__dustBody=!0;functionbody_15(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","proposalType"]),ctx,"h").w("</div>");}body_15.__dustBody=!0;functionbody_16(chk,ctx){returnchk.w("");}body_16.__dustBody=!0;functionbody_17(chk,ctx){returnchk.w("<div class=\"row\"><div class=\"col-md-12 col-xl-8\">").h("abstract",ctx,{"block":body_18},{"abstract":ctx.getPath(false,["data","abstract"])},"h").w("</br></div><div class=\"col-sm-6 col-xl-2\"><div class=\"myBorder-left\" style=\"margin-right:-15px\">").h("proposalBeamlineTable",ctx,{"block":body_19},{"mergedProposalBeamlines":ctx.getPath(false,["data","mergedProposalBeamlines"])},"h").w("</div></div><div class=\"col-sm-6 col-xl-2\" ><div class=\"myBorder-left\"><label> Publication year </label>").x(ctx.getPath(false,["data","mintingYear"]),ctx,{"else":body_20,"block":body_21},{}).w("</div></div></div>");}body_17.__dustBody=!0;functionbody_18(chk,ctx){returnchk.w("");}body_18.__dustBody=!0;functionbody_19(chk,ctx){returnchk.w("");}body_19.__dustBody=!0;functionbody_20(chk,ctx){returnchk.w("<div class=\"padding-left-15\"> Not available</div>");}body_20.__dustBody=!0;functionbody_21(chk,ctx){returnchk.w("<div class=\"padding-left-15\">").f(ctx.getPath(false,["data","mintingYear"]),ctx,"h").w("</div>");}body_21.__dustBody=!0;returnbody_0}(dust));
(function(dust){dust.register("welcome_tpl",body_0);functionbody_0(chk,ctx){returnchk.w(" <div class=\"container-fluid\"><div class=\"row\"><div class=\"col-12 flexCentered whiteFont\" style=\"color:#132577; font-size: 6.4rem; height: 200px; margin-top: 10px; margin-bottom: 10px;\">ESRF DOI Portal</div></div></div><div class=\"container-fluid\"><div class=\"row\"><div class=\"col-12 col-md-4\"><div class=\"padding10\"><div class=\"card-header text-center\"><h1 class=\"font-3p2rem\">About the portal</h1></div><div class=\"card-body padding10\">This page centralizes the <a href=\"http://www.esrf.eu/home/UsersAndScience/UserGuide/esrf-data-policy/doi.html\" target=\"_blank\"> DOI</a> services offered by the ESRF to access data stored at the facility as part of its data policy. Data referred to by ESRF DOIs are accessed via the ESRF data catalogue <a href=\"https://icat.esrf.fr\" target=\"_blank\"> icat.esrf.fr</a>.<p> In case you require a DOI for a subset of data please send an email with the following high level metadata - \"proposal\", \"title\", \"authors\", \"abstract\", \"datasets\" to datapolicy@esrf.fr </p></div></div></div><div class=\"col-12 col-md-4\"><div class=\"padding10\"><div class=\"card-header text-center \"><h1 class=\"font-3p2rem\">DOI resolver</h1></div><div class=\"card-body padding10\"><p>The search engine below only searches DOIs which have been minted at the ESRF. </br> Use <a href=\"https://doi.org\">doi.org </a> search engine for other DOIs.</p><div class=\"row\"><div class=\"col-xl-9 padding-right-0\"><p> <input id=\"doiSearchBox\" class=\"form-control\" placeholder=\"10.15151/ESRF-ES-90632078\" type=\"text\" required/> </p><div class=\"text-danger\" id=\"error\"> </div> </div><div class=\"col padding-left-0\"> <input class=\"btn btn-primary\" type=\"submit\" value=\"Search\" onclick=\"searchDOI()\" /> </div></div><div class=\"row\"><div class=\"col\"><p> <a href=\"https://search.datacite.org/works?query=10.15151\"> List all ESRF DOIs </a> </p></div></div></div> </div></div><div class=\"col-12 col-md-4\"><div class=\"padding10\"><div class=\"card-header text-center\"><h1 class=\"font-3p2rem\">About DOI </h1></div><div class=\"card-body padding10\">The Digital Object Identifier (<a href=\"http://www.esrf.eu/home/UsersAndScience/UserGuide/esrf-data-policy/doi.html\">DOI</a>) is a code composed of digits and characters. It identifies data in a unique and permanent way thereby allowing data to be referenced worldwide. The DOI has two parts, namely the DOI prefix and the DOI suffix separated by a slash (\"/\"). The ESRF prefix is 10.15151 followed by a slash and the ESRF suffix. Currently the following suffix(es) are defined:</p><pre>ESRF-ES - for a session at the ESRF </pre>Refer to the <a href=\"http://www.esrf.eu/home/UsersAndScience/UserGuide/esrf-data-policy/doi/doi---concepts.html\">DOI concepts</a> page to find out what a session is.</div></div></div></div></div>");}body_0.__dustBody=!0;returnbody_0}(dust));
"text":"Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins. The 2.1-Å crystal structure of glycosylated human afamin reveals an almost exclusively hydrophobic binding cleft capable of harboring large hydrophobic moieties. Lipid analysis confirms the presence of lipids, and density in the primary binding pocket of afamin was modeled as palmitoleic acid, presenting the native O-acylation on serine 209 in human Wnt3a. The modeled complex between the experimental afamin structure and a Wnt3a homology model based on the XWnt8-Fz8-CRD fragment complex crystal structure is compelling, with favorable interactions comparable with the crystal structure complex. Afamin readily accommodates the conserved palmitoylated serine 209 of Wnt3a, providing a structural basis how afamin solubilizes hydrophobic and poorly soluble Wnt proteins."
"description":"Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins. The 2.1-Å crystal structure of glycosylated human afamin reveals an almost exclusively hydrophobic binding cleft capable of harboring large hydrophobic moieties. Lipid analysis confirms the presence of lipids, and density in the primary binding pocket of afamin was modeled as palmitoleic acid, presenting the native O-acylation on serine 209 in human Wnt3a. The modeled complex between the experimental afamin structure and a Wnt3a homology model based on the XWnt8-Fz8-CRD fragment complex crystal structure is compelling, with favorable interactions comparable with the crystal structure complex. Afamin readily accommodates the conserved palmitoylated serine 209 of Wnt3a, providing a structural basis how afamin solubilizes hydrophobic and poorly soluble Wnt proteins.",
// "text": "Afamin, a human plasma glycoprotein and putative transporter of hydrophobic molecules, has been shown to act as extracellular chaperone for poorly soluble, acylated Wnt proteins, forming a stable, soluble complex with functioning Wnt proteins. The 2.1-Å crystal structure of glycosylated human afamin reveals an almost exclusively hydrophobic binding cleft capable of harboring large hydrophobic moieties. Lipid analysis confirms the presence of lipids, and density in the primary binding pocket of afamin was modeled as palmitoleic acid, presenting the native O-acylation on serine 209 in human Wnt3a. The modeled complex between the experimental afamin structure and a Wnt3a homology model based on the XWnt8-Fz8-CRD fragment complex crystal structure is compelling, with favorable interactions comparable with the crystal structure complex. Afamin readily accommodates the conserved palmitoylated serine 209 of Wnt3a, providing a structural basis how afamin solubilizes hydrophobic and poorly soluble Wnt proteins."
"text":"Afamin, a human blood plasma glycoprotein, a putative multi-functional transporter of hydrophobic molecules and a marker for metabolic syndrome, poses multiple challenges for crystallographic structure determination, both practically and in analysis of the models. Several hundred crystals were analysed, and unusual variability in cell volume and difficulty solving the structure despite a ~34% sequence identity with non-glycosylated human serum albumin indicated that the molecule exhibits variable and context-sensitive packing, despite greatly simplified glycosylation in insect cell expressed recombinant afamin. Controlled dehydration of the crystals was able to stabilise the orthorhombic crystal form reducing the number of molecules in the asymmetric unit from the monoclinic form and changing the conformational states of the protein. An iterative strategy using fully automatic experiments available on MASSIF-1 was used to quickly determine the optimal protocol to achieve the phase transition that should be readily applicable to many types of sample. The study also highlights the drawback of using a single crystallographic structure model for computation modelling purposes given that conformational state of the binding sites and electron density in the binding site, likely resulting from PEGs, greatly varies between models. This also holds for the analysis of unspecific low-affinity ligands, where often a variety fragments with similar uncertainty can be modelled, inviting interpretative bias. As a promiscuous transporter, afamin can also bind Gadoteridol, a magnetic resonance imaging contrast compound in two sites, one near the human albumin Sudlow-site and a second hitherto unknown binding site."
"description":"Afamin, a human blood plasma glycoprotein, a putative multi-functional transporter of hydrophobic molecules and a marker for metabolic syndrome, poses multiple challenges for crystallographic structure determination, both practically and in analysis of the models. Several hundred crystals were analysed, and unusual variability in cell volume and difficulty solving the structure despite a ~34% sequence identity with non-glycosylated human serum albumin indicated that the molecule exhibits variable and context-sensitive packing, despite greatly simplified glycosylation in insect cell expressed recombinant afamin. Controlled dehydration of the crystals was able to stabilise the orthorhombic crystal form reducing the number of molecules in the asymmetric unit from the monoclinic form and changing the conformational states of the protein. An iterative strategy using fully automatic experiments available on MASSIF-1 was used to quickly determine the optimal protocol to achieve the phase transition that should be readily applicable to many types of sample. The study also highlights the drawback of using a single crystallographic structure model for computation modelling purposes given that conformational state of the binding sites and electron density in the binding site, likely resulting from PEGs, greatly varies between models. This also holds for the analysis of unspecific low-affinity ligands, where often a variety fragments with similar uncertainty can be modelled, inviting interpretative bias. As a promiscuous transporter, afamin can also bind Gadoteridol, a magnetic resonance imaging contrast compound in two sites, one near the human albumin Sudlow-site and a second hitherto unknown binding site.",
